Clinical Trial Update: Brentuximab Vedotin Plus AVD in Limited-stage Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating brentuximab vedotin plus AVD in limited-stage Hodgkin lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma

Drugs mentioned

• AVD (doxorubicin, vinblastine, dacarbazine)
• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Hodgkin Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2017-08-30